It is evident that dysregulation of the DDR2-collagen-LOXL2 axis in early prostate cancer would therefore provide a potent and pro-tumorigenic microenvironment, capable of driving aggressive disease and that this axis can be targeted with therapeutic interventions. Here, LOXL2 is linked to prostate cancer.